Oral GLP-1 care requires choosing the exact product and approved purpose. Foundayo and Wegovy tablets offer adult weight-management options.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Oral GLP-1 care requires choosing the exact product and approved purpose. Foundayo and Wegovy tablets offer adult weight-management options. Ozempic tablets and Rybelsus treat adult type 2 diabetes. Their dosing and eating instructions differ.
Weight-management tablets are for qualifying adults after a safety review. Having PCOS or wanting to avoid injections does not alone establish eligibility. Diabetes tablets should not be described as approved obesity medicines.
Review your diagnosis, current medicine, other oral drugs, contraception, and morning routine. Choose the exact tablet and teach its instructions. Check insurance and pharmacy access separately from the visit. Switching from an injection or another tablet needs a prescriber’s plan, not a milligram conversion.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Foundayo requires additional or non-oral contraception for 30 days after starting and each dose increase. Oral semaglutide products have their own pregnancy and breastfeeding instructions.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
No. Insurance payment for the consultation does not guarantee payment for the medicine, testing or administration. Confirm the exact product and indication with the plan, including authorization, benefit rules and expected cost. Ask the clinic which services it provides and how each part of care will be billed.
Ask for separate current estimates for the evaluation, required tests, medicine, administration when relevant, and follow-up. Drug costs depend on product, dose, coverage, pharmacy, and savings eligibility. Self-pay still requires clinical review and monitoring. Confirm any manufacturer program’s current terms directly; a posted price does not guarantee your final cost.
Approval cannot be guaranteed. The plan reviews the exact treatment, indication and submitted records against its rules. Bring any denial or information request so the clinician can address the stated reason. Confirm the actual decision and remaining costs before relying on authorization as a treatment start.
As of October 9, 2026, Medicare’s GLP-1 Bridge includes Foundayo and Wegovy tablets for eligible adults with Part D coverage, with a $50 monthly copayment. It began July 1, 2026 and runs through December 31, 2027. Eligibility includes BMI 35 or higher. With BMI 30 or higher, qualifying conditions include heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or later kidney disease. With BMI 27 or higher, they include prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People already receiving Part D-covered GLP-1s and those with type 2 diabetes, moderate-to-severe obstructive sleep apnea or noncirrhotic MASH with moderate-to-advanced fibrosis are excluded; their usual Part D benefits may apply instead. A prescription, lifestyle-program certification and required authorization are needed. Ask the prescriber and Medicare to check your eligibility. The copayment does not count toward the Part D deductible or out-of-pocket limit.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
